company background image
CYCN logo

Cyclerion Therapeutics NasdaqCM:CYCN Stock Report

Last Price

US$3.20

Market Cap

US$8.1m

7D

-9.3%

1Y

-25.6%

Updated

23 Dec, 2024

Data

Company Financials

Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$8.1m

My Notes

Capture your thoughts, links and company narrative

Cyclerion Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cyclerion Therapeutics
Historical stock prices
Current Share PriceUS$3.20
52 Week HighUS$9.47
52 Week LowUS$1.27
Beta1.82
1 Month Change123.78%
3 Month Change11.50%
1 Year Change-25.58%
3 Year Change-90.36%
5 Year Change-94.07%
Change since IPO-98.72%

Recent News & Updates

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

Shareholder Returns

CYCNUS BiotechsUS Market
7D-9.3%-3.3%-2.2%
1Y-25.6%-1.9%23.9%

Return vs Industry: CYCN underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: CYCN underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is CYCN's price volatile compared to industry and market?
CYCN volatility
CYCN Average Weekly Movement88.1%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: CYCN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CYCN's weekly volatility has increased from 49% to 88% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20181n/awww.cyclerion.com

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics, Inc. Fundamentals Summary

How do Cyclerion Therapeutics's earnings and revenue compare to its market cap?
CYCN fundamental statistics
Market capUS$8.07m
Earnings (TTM)-US$5.28m
Revenue (TTM)US$194.00k

41.7x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYCN income statement (TTM)
RevenueUS$194.00k
Cost of RevenueUS$1.32m
Gross Profit-US$1.12m
Other ExpensesUS$4.16m
Earnings-US$5.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.09
Gross Margin-577.84%
Net Profit Margin-2,722.16%
Debt/Equity Ratio0%

How did CYCN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:34
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclerion Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Martin AusterCredit Suisse
Joon So LeeTruist Securities